BioCentury | Apr 1, 2013
Clinical News

Viscogel: Phase I/II data

...single-blind, Swedish Phase I/II trial in about 130 healthy volunteers showed that single ascending-doses of ViscoGel...
...ViVac, a project aimed at developing ViscoGel as an adjuvant in prophylactic and therapeutic vaccination. Viscogel...
...part of ViVac. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets ActHIB. Viscogel AB , Solna, Sweden Product: Viscogel...
BioCentury | Apr 30, 2012
Clinical News

Viscogel: Phase I/II started

...ViscoGel in about 130 healthy volunteers. The Phase I portion will evaluate single ascending-doses of ViscoGel...
...other European companies and academic institutions as part of ViVac. Viscogel AB , Solna, Sweden Product: Viscogel...
Items per page:
1 - 2 of 2
BioCentury | Apr 1, 2013
Clinical News

Viscogel: Phase I/II data

...single-blind, Swedish Phase I/II trial in about 130 healthy volunteers showed that single ascending-doses of ViscoGel...
...ViVac, a project aimed at developing ViscoGel as an adjuvant in prophylactic and therapeutic vaccination. Viscogel...
...part of ViVac. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets ActHIB. Viscogel AB , Solna, Sweden Product: Viscogel...
BioCentury | Apr 30, 2012
Clinical News

Viscogel: Phase I/II started

...ViscoGel in about 130 healthy volunteers. The Phase I portion will evaluate single ascending-doses of ViscoGel...
...other European companies and academic institutions as part of ViVac. Viscogel AB , Solna, Sweden Product: Viscogel...
Items per page:
1 - 2 of 2